Sovaldi is currently priced at approximately $1,000 a pill, a total of $84,000 or more for a full course of treatment. But, Gilead Sciences intends to release a new interferon-free HCV treatment in October. The release of the new drug is expected to drive down costs.
During the briefing, Gilead Sciences Vice President Coy Stout and two cured HCV patients argued that the drug’s cost is less than that of a liver transplant.
More articles on gastroenterology:
Why do gastroenterologists need a GI-specific EMR system?
Is the MD/MBA combination the key to navigating healthcare today?
CRC test ColoMarker receives CE mark
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
